Skip to main content
Premium Trial:

Request an Annual Quote

Judge Triples Damages in Third Wave s Patent-Infringement Suit Against Stratagene

NEW YORK, Dec. 19 (GenomeWeb News) - Third Wave Technologies said today that a federal judge overseeing its patent infringement suit against Stratagene has tripled the damages awarded to $15.9 million and ruled that Stratagene must pay Third Wave's attorney fees.


In September, a federal court ruled that Stratagene infringed two patents covering Third Wave's Invader technology.


Later that month, the court found Stratagene liable for willful patent infringement and awarded Third Wave $5.3 million in damages. The court also prohibited Stratagene from making, selling, or offering to sell its FullVelocity QPCR and QRT-PCR products.


Third Wave said today that it "sought the additional damages, given the willful infringement verdict."


Kevin Conroy, president and CEO of Third Wave, said in a statement today that the increase in damages "will send a strong signal to others who would infringe Third Wave's unique and valuable intellectual property."


Stratagene officials were not immediately available for comment.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.